Ipsen Press Releases | Latest News & Updates

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 243 Press Releases

Show

Sort

28 May 2026

28 May 2026

Download New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC

New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC

19 May 2026

19 May 2026

Download Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

16 May 2026

16 May 2026

Download Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

15 May 2026

15 May 2026

Download Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

14 May 2026

14 May 2026

Download Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium

Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium

Your dedicated contacts

Media Relations

+33 1 58 33 50 00

IpsenMediaRelations@ipsen.com

Add to contacts

Stay updated

Register to receive our latest news